{"filing":{"accession_number":"0001493152-26-035867","cik":"0001716166","ticker":"VVOS","company_name":"Vivos Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-31","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/form8-k.htm"},"events":[{"id":23261,"run_id":21031,"accession_number":"0001493152-26-035867","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both the departure of Bradford Amman as CFO and the appointment of Roman Franklin as CFO, effective July 31, 2026. While both events occur, the principal disclosed action centers on the appointment of Franklin as the new CFO with a detailed background and compensatory arrangements under a Master Services Agreement with CFO Portal. The departure is presented as context for the transition. The appointment of a new CFO with material compensation terms (annual retainer of $324,000 plus equity awards) is material to investors assessing leadership and financial management continuity.","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":23448,"accession_number":"0001493152-26-035867","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of Bradford Amman as CFO and the appointment of Roman Franklin as CFO, effective July 31, 2026. While both events occur, the principal disclosed action centers on the appointment of Franklin as the new CFO with a detailed background and compensatory arrangements under a Master Services Agreement with CFO Portal. The departure is presented as context for the transition. The appointment of a new CFO with material compensation terms (annual retainer of $324,000 plus equity awards) is material to investors assessing leadership and financial management continuity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:54:02.014843+00:00","company_name":"Vivos Therapeutics, Inc.","ticker":"VVOS","filing_date":"2026-08-03"}]}